LLY · News · 20260901N
Reimbursement and Payer Mix - GLP-1
ELI LILLY & Co · 2026-09-01 · Importance 32 · Surprise 24 · In source text
Employer coverage for GLP-1 weight-loss drugs is decreasing, creating reimbursement pressure for Zepbound and other obesity treatments. Lilly’s expanded Mounjaro label covering cardiovascular risk reduction in patients with type 2 diabetes could support medical-necessity arguments for continued payer coverage. A Lilly study also reported that patients older than 55 using Zepbound incurred lower healthcare costs than comparable non-users, potentially strengthening the case for expanded Zepbound coverage.
Key facts
- Mounjaro's revenue has seen significant growth, driven by volume despite pricing declines, leading Lilly to raise its full-year guidance. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Mounjaro's revenue has seen significant growth, driven by volume despite pricing declines, leading Lilly to raise its full-year guidance. |